Goldman Sachs analysts removed Edwards Lifesciences from the firm’s US Conviction List as part of its August update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences upgraded to Peer Perform from Underperform at Wolfe Research
- Edwards Lifesciences price target lowered to $90 from $101 at Barclays
- Edwards Lifesciences (NYSE:EW) Plunges 31% after J.P. Morgan and Truist Downgrades
- Edwards Lifesciences price target lowered to $85 from $101 at RBC Capital
- Edwards Lifesciences falls -28.3%